CHARLESTOWN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company ...

This review will focus on the diagnosis, risk stratification and treatment of the most common and well described IA syndromes, namely long QT syndrome (LQTS), Brugada syndrome (BrS) and ...

The ideal is for the examination to be performed by a specialist cardiac pathologist with appropriate samples being taken for histological and genetic analysis. The autopsy will be unhelpful in ...

Such techniques can be automatically applied using implantable cardioverter defibrillators (ICDs) and offer the potential for painless termination of ventricular tachycardia (VT). Reduction in ...

Fintel reports that on December 13, 2024, Guggenheim downgraded their outlook for Boundless Bio (NasdaqGS:BOLD) from Buy to ...

Its development of a gene therapy candidate for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) addresses a significant unmet need with minimal competition, potentially opening new ...

Its product pipeline include SGT-003 for duchenne muscular dystrophy, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and AVB-401 for BAG3-mediated dilated cardiomyopathy, among ...

Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular ...

Though Curtis Cazier’s name has become more known across Cache Valley recently — due to saving the life of a student who went ...

Ablation sites (maroon circular tags) abolished ventricular tachycardia in this patient.

Catheter ablation is the primary treatment option for idiopathic ventricular tachycardia (VT). It plays a key role in acute therapy of electrical storm, treatment of VTs in patients with structural ...